Pancreatic ductal adenocarcinoma (PDAC) is defined by a dense, immunosuppressive tumor microenvironment (TME) enriched with extracellular matrix components, cancer-associated fibroblasts (CAFs), and diverse immune populations. ChIP-seq analysis of resected human PDAC identified MICAL2 as a super-enhancer–associat...
Bharti Garg, E. Mose, Briana Nyugen et al.· Cancer Research· 0 citations
Leveraging the MITF-dependent gene signature activated in macrophages, this work sought to address how MITF-associated enhancers are mechanistically influencing PDAC TAM functions as the tumor becomes more advanced and develops chemoresistance.
Debbie K. Ledezma, K. Gulay, Hervé Tiriac et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is a deadly form of pancreatic cancer with the poorest 5-year survival rate among all solid cancers. Therefore, identifying effective therapeutic strategies is crucial for treating this disease. Using a genome-wide screening approach to find novel and targetable factors in huma...
Nirakar Rajbhandari, Deepa Sheik Pran Babu, E. Mose et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.